Tarsus Pharmaceuticals Inc (NASDAQ:TARS) — Market Cap & Net Worth
Market Cap & Net Worth: Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) has a market capitalization of $3.43 Billion ($3.43 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4525 globally and #1549 in its home market, demonstrating a -13.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tarsus Pharmaceuticals Inc's stock price $78.23 by its total outstanding shares 43882996 (43.88 Million). Also see Tarsus Pharmaceuticals Inc (TARS) total assets for a full breakdown of the balance sheet.
Tarsus Pharmaceuticals Inc Market Cap History: 2020 to 2026
Tarsus Pharmaceuticals Inc's market capitalization history from 2020 to 2026. Data shows growth from $1.81 Billion to $3.43 Billion (25.31% CAGR). Also see TARS cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Tarsus Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.13% | #118 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.01% | #519 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.18% | #77 of 263 |
Weight: Tarsus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tarsus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tarsus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TARS stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.96x
Tarsus Pharmaceuticals Inc's market cap is 7.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.81 Billion | $33.43 Million | -$26.81 Million | 54.25x | N/A |
| 2021 | $987.37 Million | $57.03 Million | -$13.83 Million | 17.31x | N/A |
| 2022 | $643.32 Million | $25.82 Million | -$62.09 Million | 24.92x | N/A |
| 2023 | $888.63 Million | $17.45 Million | -$135.89 Million | 50.93x | N/A |
| 2024 | $2.43 Billion | $182.95 Million | -$115.55 Million | 13.28x | N/A |
| 2025 | $3.59 Billion | $451.36 Million | -$66.42 Million | 7.96x | N/A |
Competitor Companies of TARS by Market Capitalization
Companies near Tarsus Pharmaceuticals Inc in the global market cap rankings as of September 16, 2026. Review Tarsus Pharmaceuticals Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tarsus Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Tarsus Pharmaceuticals Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Tarsus Pharmaceuticals Inc's market cap moved from $1.81 Billion to $ 3.43 Billion, with a yearly change of 25.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.43 Billion | -4.46% |
| 2025 | $3.59 Billion | +47.88% |
| 2024 | $2.43 Billion | +173.43% |
| 2023 | $888.63 Million | +38.13% |
| 2022 | $643.32 Million | -34.84% |
| 2021 | $987.37 Million | -45.56% |
| 2020 | $1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Tarsus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.43 Billion USD |
| MoneyControl | $3.43 Billion USD |
| MarketWatch | $3.43 Billion USD |
| marketcap.company | $3.43 Billion USD |
| Reuters | $3.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more